UpStreAm doxycycline in ST-eLeVation myocArdial infarction: targetinG infarct hEaling and ModulatIon (SALVAGE-MI trial)
Authors' conclusion
Doxycycline prior to PPCI neither reduced IS acutely or at six months nor attenuated adverse LV remodelling.
Study context
- Population
- Patients with ST-elevation myocardial infarction (STEMI) undergoing primary PCI
- Participants
- 103 patients
- Comparison
- Doxycycline vs placebo before reperfusion in STEMI
- Doxycyclinen = 50
- Placebon = 53reference
- Primary endpoint
- Final infarct size adjusted for area-at-risk (fIS/AAR) on two CMR scans ∼6 months apart
- Follow-up
- ∼6 months
Methodological detailsdouble-blind, placebo-controlled
- Double-blind
- Placebo-controlled
Primary result
As reported in the abstract
fIS/AAR
Doxycycline
0.79
range 0.5–0.9
Placebo
0.61
range 0.47–0.76
P = 0.06
Further findings
| Outcome | Doxycycline | Placebo | Regression coefficient | P value |
|---|---|---|---|---|
| Final IS · 6 months | 18.8% (range 12–26) | 13.6% (range 11–21) | P = 0.08 | |
| Acute IS | 21.7% (range 17–34) | 19.4% (range 14–27) | P = 0.19 | |
| AAR | 26% (range 20–36) | 24.7% (range 16–31) | P = 0.22 | |
| Adverse LV remodelling (%Δ end-diastolic volume index) | 1.1% (range −3.8–8.4) | −1.34% (range −6.1–5.8) | P = 0.42 | |
| Independent association of doxycycline with fISAssociated with larger fIS | 0.175 | P = 0.03 |
Original publication
UpStreAm doxycycline in ST-eLeVation myocArdial infarction: targetinG infarct hEaling and ModulatIon (SALVAGE-MI trial). Eur Heart J Acute Cardiovasc Care. Published 26 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →